Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 6.9% – What’s Next?

Marker Therapeutics, Inc. (NASDAQ:MRKR)’s share price traded down 6.9% on Wednesday . The company traded as low as $1.10 and last traded at $1.1450. 103,065 shares changed hands during mid-day trading, an increase of 122% from the average session volume of 46,424 shares. The stock had previously closed at $1.23.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a research report on Wednesday, June 24th. HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $10.00.

Marker Therapeutics Stock Performance

The company has a market capitalization of $19.09 million, a price-to-earnings ratio of -1.88 and a beta of 1.50. The firm’s 50-day simple moving average is $1.37 and its 200-day simple moving average is $1.46.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The business had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. Equities research analysts forecast that Marker Therapeutics, Inc. will post -1.17 earnings per share for the current year.

Institutional Trading of Marker Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRKR. Jane Street Group LLC acquired a new position in Marker Therapeutics in the second quarter worth about $33,000. Two Sigma Investments LP acquired a new position in shares of Marker Therapeutics in the 3rd quarter worth approximately $33,000. Virtu Financial LLC acquired a new position in shares of Marker Therapeutics in the 3rd quarter worth approximately $25,000. Boyer Financial Services Inc. bought a new position in shares of Marker Therapeutics during the 4th quarter worth approximately $57,000. Finally, Geode Capital Management LLC boosted its stake in Marker Therapeutics by 35.3% in the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after buying an additional 34,028 shares in the last quarter. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.